BHB-1893 tested against metoprolol for obstructive hypertrophic cardiomyopathy
Tests BHB-1893 against metoprolol in adults with heart thickening causing symptoms.
Plain-language title generated from the registry record
Registry title: BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Key facts
- Where
- Burlington, Manhasset, Plano, and Rock Hill, United StatesSee the 4 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07755904, who can take part
Where in United States
- BurlingtonBurlington, United StatesTaking people
- ManhassetManhasset, United StatesTaking people
- PlanoPlano, United StatesTaking people
- Rock HillRock Hill, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Braveheart Bio, Inc.
- Trial code
- NCT07755904EU 2026-526007-30-00
- Record updated
- 10 November 2026
- Original description
The main purpose of this trial is to find out whether BHB-1893 works better than metoprolol in adults with symptoms of obstructive hypertrophic cardiomyopathy (oHCM). The trial includes adults who are currently being treated for oHCM or who have not yet been treated.Read full original descriptionShow less
A Phase 3, Multi-region, Multi-center, Randomized, Double-blind, Active-Comparator-Controlled Trial to Evaluate the Efficacy and Safety of BHB-1893 Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
The main purpose of this trial is to find out whether BHB-1893 works better than metoprolol in adults with symptoms of obstructive hypertrophic cardiomyopathy (oHCM). The trial includes adults who are currently being treated for oHCM or who have not yet been treated.
Inclusion: Diagnosed with oHCM per the protocol specified criteria; NYHA Class II or III at screening visits; KCCQ-CSS that meets the protocol specified criteria at screening visits; Adequate acoustic windows for echocardiography.
Exclusion: History of intolerance or medical contraindication to β-blocker therapy; Resting heart rate of >100 beats per minute (bpm) at screening visits; Significant valvular heart disease, defined as:; Moderate to severe valvular aortic stenosis or fixed subaortic obstruction; Mitral regurgitation not due to systolic anterior motion of the mitral valve (per Investigator's judgment); Other protocol-defined criteria apply; Medical indication for either β-blocker or calcium-channel blocker therapy, other than oHCM, prohibiting drug discontinuation; Resting systolic blood pressure (SBP) of >160 millimeters of mercury (mmHg) at screening visits.